Physician profile
Andrew Smith
NPI 1215460670
$3,571.21
in general payments reported to CMS, 2019-2025
13 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $197 · 2021: $678 · 2022: $760 · 2023: $1,578 · 2024: $254 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Food and Beverage | $886.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $1,050.00 | 2023 | |
| Alcon Vision LLC | $971.58 | 2020-2025 | Rocklatan, Hydrus Microstent |
| Glaukos Corporation | $381.81 | 2022-2025 | Istent Infinite, Kxl System (Not Refurbished), Idosetr |
| Abbvie INC. | $331.17 | 2022-2024 | Xen Glaucoma Treatment System |
| New World Medical,INC. | $206.71 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $172.42 | 2021-2024 | Tecnis Simplicity |
| Allergan, INC. | $139.77 | 2021-2022 | |
| Sight Sciences, INC. | $120.35 | 2021-2022 | |
| Baxter Healthcare | $92.22 | 2024 | |
| Bausch & Lomb Americas INC. | $29.29 | 2023 | Vyzulta |
| Regeneron Healthcare Solutions, INC. | $26.44 | 2025 | Dupixent |
| Thea Pharma INC. | $24.96 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.